Lilly’s Verve Gambit Pays Off as Base Editor Cuts Cholesterol in Early Study

Eli Lilly's VERVE-102 Base Editor Shows Strong Efficacy in Phase 1b

Eli Lilly's investigational base editor, VERVE-102, demonstrated substantial and sustainable reductions in disease biomarkers in a Phase 1b study for heterozygous familial hypercholesterolemia (HeFH). A single 1 mg/kg dose lowered LDL-C by up to 62% and PCSK9 by 51% to 88%. This success validates Lilly's $1.3 billion acquisition of Verve Therapeutics, with the company planning to advance VERVE-102 into Phase 2 development before the year ends, supporting its potential as a one-time treatment for hypercholesterolemia.

• The Phase 1b Heart-2 trial showcased significant efficacy for VERVE-102, Eli Lilly's base editor. A single high dose of 1 mg/kg resulted in a remarkable reduction of low-density lipoprotein cholesterol (LDL-C) by up to 62% in patients with heterozygous familial hypercholesterolemia (HeFH) or premature coronary artery disease (CAD). Furthermore, patients experienced a substantial decrease in PCSK9 levels, ranging from 51% to 88%, indicating a strong biological impact on a key protein regulating LDL-C receptors.
• VERVE-102 is being evaluated in the ongoing Phase 1b Heart-2 trial, specifically targeting patients diagnosed with heterozygous familial hypercholesterolemia or premature coronary artery disease who require additional support to lower their LDL-C levels. The drug is administered via intravenous delivery, encapsulated within a lipid nanoparticle, and functions by deactivating the PCSK9 gene. Following these encouraging early-stage results, Eli Lilly is set to advance VERVE-102 into mid-stage development, with a Phase 2 study anticipated to commence before the end of the current year.
• The positive Phase 1b data for VERVE-102 vindicate Eli Lilly's strategic $1.3 billion acquisition of Verve Therapeutics in June 2025, an investment that initially drew skepticism from analysts regarding the commercial viability of gene therapies for cholesterol. Despite ongoing questions from some market observers about the true need for gene editing in the context of existing and emerging lipid-lowering agents, Lilly's success underscores its commitment to the gene therapy modality and its potential to complement the company's extensive cardio-metabolic expertise.

VERVE-102 Shows Strong LDL-C Reduction in HeFH Phase 1b

Recent clinical trials in heterozygous familial hypercholesterolemia (HeFH) have demonstrated significant advances in lipid-lowering therapies, including novel oral PCSK9 inhibitors and innovative gene therapies. These studies highlight substantial LDL-C reductions across diverse patient populations while maintaining acceptable safety profiles.

• BROOKLYN Trial (2026) - Obicetrapib: Randomized trial testing obicetrapib 10 mg daily (highly selective cholesteryl ester transfer protein inhibitor) in 354 patients with HeFH; primary endpoint at day 84 showed placebo-adjusted LDL cholesterol reduction of -36.3% (95% CI: -42.2% to -30.4%, P<0.0001); secondary endpoints included apolipoprotein B reduction of -24.4%, non-HDL cholesterol reduction of -34.5%, lipoprotein(a) reduction of -45.9%, and HDL cholesterol increase of +138.7%; well tolerated with no significant safety concerns

• Enlicitide Phase 3 Trial (2025): Novel oral PCSK9 inhibitor tested in 303 HeFH participants (mean age 52.4 years, 51% female) with baseline LDL-C of 119.0 mg/dL; 20 mg once daily for 52 weeks achieved -58.2% LDL-C reduction vs 2.6% placebo at week 24 (between-group difference -59.4%, P<0.001) and sustained -55.3% reduction at week 52; secondary outcomes included non-HDL-C reduction of -52.3%, apolipoprotein B reduction of -48.2%, and lipoprotein(a) reduction of -24.7%; well tolerated with similar adverse event rates between groups and 96.7% trial completion rate

• YOLT-101 Gene Therapy Trial (2026): First-in-human Phase 1 trial of in vivo base-editing gene therapy using adenine base-editing technology to inactivate PCSK9; 6 participants with HeFH received single intravenous doses (0.2-0.6 mg/kg); highest dose achieved sustained PCSK9 reduction of 74.4% and LDL-C reduction of 52.3% at 24 weeks; no grade ≥3 adverse events occurred, with most common side effects being transient infusion-related reactions and liver enzyme elevations

• REMAIN-3 Trial (Recaticimab, 2025): Phase 3 study of recaticimab (humanized anti-PCSK9 antibody) in 143 Chinese HeFH patients; 150 mg subcutaneously every 4 weeks for 12 weeks achieved mean LDL-C reduction of -54.4% vs -4.5% placebo (treatment difference -49.8%, P<0.0001); treatment-related adverse events comparable between groups (27.4% vs 25.0%), with injection site reactions (8.4% vs 0%) and elevated creatine phosphokinase (5.3% vs 2.1%) most common

• Inclisiran Post Hoc Analysis in CKD Patients (2026): Pooled analysis of three Phase 3 trials (ORION-9, -10, -11) in 3660 HeFH patients stratified by kidney function; subcutaneous inclisiran every 6 months achieved consistent LDL-C reductions across all eGFR groups ranging from -44.7% to -55.6% at day 510 (all P<0.001); significant improvements in total cholesterol, apolipoprotein B, non-HDL cholesterol, and lipoprotein(a) across all kidney function categories; well tolerated without new safety findings

• Pediatric HeFH Systematic Review (2026): Comprehensive analysis of pediatric treatment options showing statins achieved significant LDL-cholesterol reduction vs placebo over 2-year follow-up (mean difference -32.15%, moderate certainty evidence); ezetimab demonstrated LDL-C reduction of -63 mg/dL, while PCSK9 inhibitors (evolocumab and alirocumab) showed -43.3% and -33.8% reductions respectively; no significant differences in adverse events during short-term follow-up between study groups for all drugs, though long-term safety requires further investigation

Understanding HeFH: The Role of PCSK9 in Cholesterol Regulation

Heterozygous familial hypercholesterolemia (HeFH) is primarily caused by pathogenic variants in three main genes: LDLR, APOB, and PCSK9, which are responsible for this autosomal dominant disease with a prevalence of approximately 1:300. The most common cause involves deleterious mutations in the LDLR gene encoding the low-density lipoprotein receptor, which plays a critical role in cholesterol metabolism by facilitating the removal of cholesterol-laden LDL particles from the bloodstream through hepatocyte internalization. Additional genetic contributors include variants in LDLRAP1 (causing recessive inheritance), specific APOE variants, and genes associated with phenocopies such as ABCG5, ABCG8, CYP27A1, and LIPA, which can mimic FH in patients without causative variants or act as phenotype modifiers.

The molecular pathogenesis centers on defective LDL catabolism resulting from impaired receptor function, leading to significantly reduced LDL uptake and subsequent cholesterol accumulation in the subendothelial space of blood vessel walls, triggering atherogenesis and atherosclerotic plaque formation. LDLR mutations exhibit high allelic heterogeneity, with approximately 50% classified as class 2 mutations where mutant proteins are partially or entirely retained in the endoplasmic reticulum and degraded via the proteasome pathway. APOB mutations, particularly the common Arg3500Gln substitution causing familial defective apolipoprotein B-100, prevent normal LDL binding to the receptor, while PCSK9 gain-of-function mutations contribute to the hypercholesterolemic phenotype, though loss-of-function variants can be protective.

The cellular mechanisms involve disrupted intramolecular interactions and reduced protein stability of the LDLR, altered interactions between the receptor and its ligands (apolipoprotein B and E), and impaired LDL binding and uptake in various cell types including activated T-lymphocytes. Recent studies have identified novel mutations across different populations, with carriers showing reduced LDL binding capacity and altered receptor expression on cell surfaces. The phenotypic variability observed among patients can be partially explained by the presence of modifier gene variants, polygenic risk scores, and the specific functional class of the mutation, with the mutation type rather than inheritance pattern being the dominating factor in determining disease severity.

VERVE-102's Place in the Evolving HeFH Treatment Landscape

The heterozygous familial hypercholesterolemia treatment landscape has undergone substantial transformation over the past five years, marked by the introduction of novel therapeutic mechanisms and significant advances in both adult and pediatric management. Traditional statin-based therapy remains foundational, with systematic reviews confirming cardiovascular risk reduction across major adverse events, coronary heart disease, and mortality outcomes. However, real-world data consistently demonstrates suboptimal goal achievement, with only 18.5% of patients reaching LDL-C targets below 55 mg/dL and significant therapeutic gaps persisting even with combination statin-ezetimibe therapy.

The most notable evolution involves the emergence of innovative therapeutic classes that have expanded treatment options beyond conventional approaches. PCSK9 inhibition has advanced significantly with the development of enlicitide, the first oral PCSK9 inhibitor to reach Phase 3 trials, demonstrating remarkable efficacy with 58.2% LDL-C reduction at 24 weeks and sustained 55.3% reduction at 52 weeks in HeFH patients. Simultaneously, CETP inhibition has gained prominence through obicetrapib trials, showing 32.6 percentage point greater LDL-C reduction compared to placebo in the BROADWAY trial, along with substantial improvements in apolipoprotein B, non-HDL cholesterol, and lipoprotein(a) levels. RNA-targeted therapies have also matured, with inclisiran providing sustained LDL-C reductions exceeding 50% for at least six months, while ANGPTL3 inhibitors like zodasiran have demonstrated profound effects with ANGPTL3 reductions of 85.4% and triglyceride reductions of 67.1% in Phase 1 trials.

The pediatric treatment paradigm has simultaneously evolved with increased emphasis on early intervention and genetic confirmation. Recent registry data reveals that 78.9% of pediatric HeFH patients now receive lipid-lowering therapy within three years of diagnosis, with statin monotherapy comprising 43.9% of treatments and combination statin-ezetimibe accounting for 11.5%. However, significant challenges persist, as only 26.1% of pediatric patients achieve LDL-C goals despite treatment, and meta-analysis data shows that while pooled LDL-C reductions of 33.44% are achievable, substantial therapeutic gaps remain across most countries. The landscape has also revealed concerning disparities in access to advanced therapies, with real-world data demonstrating that White, higher-income, and better-educated patients are significantly more likely to receive intensive lipid-lowering treatments including PCSK9 inhibitors and combination therapies, highlighting the need for more equitable therapeutic access as the treatment armamentarium continues to expand.

Base Editing's Leap Towards Durable Hypercholesterolemia Treatment

The recent Phase 1b data for VERVE-102 marks a pivotal moment for gene editing in cardiovascular medicine. Achieving substantial and durable reductions in LDL-C and PCSK9 with a single dose of this investigational base editor for heterozygous familial hypercholesterolemia (HeFH) is more than just a clinical success; it represents a significant leap towards realizing the promise of "one-and-done" therapies for chronic diseases. This approach fundamentally shifts the paradigm from lifelong medication adherence to a single intervention designed for lasting impact, offering unprecedented opportunities to prevent atherosclerotic cardiovascular disease.

This positive outcome not only validates Eli Lilly's strategic acquisition of Verve Therapeutics but also bolsters confidence in the broader base editing platform. The technology, which enables precise single-nucleotide changes without inducing double-strand DNA breaks, is demonstrating its potential beyond theoretical applications, moving firmly into clinical reality. Such advancements could pave the way for similar gene editing strategies across a spectrum of inherited and acquired disorders.

However, as with any groundbreaking technology, critical considerations remain:

• Precision and Off-Target Effects: While base editing aims for high precision, the potential for unintended genome-wide or transcriptome-wide modifications requires continuous vigilance and long-term safety assessments.

• Delivery Challenges: Ensuring efficient and specific delivery of the editing machinery to the intended cells, primarily hepatocytes in this case, without affecting other tissues, is crucial for maximizing efficacy and minimizing systemic risks.

• Long-Term Durability and Safety: The permanent nature of genetic modification necessitates extensive follow-up to fully understand the sustained therapeutic benefits and any potential late-onset adverse events over a patient's lifetime.

If these challenges are successfully navigated, VERVE-102 could redefine the treatment landscape for hypercholesterolemia, offering a transformative solution that could significantly reduce the global burden of cardiovascular disease.